FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167622011> ?p ?o ?g. }

• W2167622011 endingPage "519.e2" @default.
• W2167622011 startingPage "513" @default.
• W2167622011 abstract "Purpose To report on the two-year visual outcomes of indocyanine green angiography-guided photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients. Design Retrospective case study. Methods A retrospective analysis that examined the clinical and angiographic data related to 41 eyes of 38 PCV patients (25 males, 13 females; average age ± standard deviation [SD], 72.9 ± 7.4 years) with follow-up periods of 24 months or more. Results The average number of PDT treatments was 1.65. After the 12-month follow-up, 12 eyes required retreatment. Although the mean visual acuity (VA) ± SD before PDT (0.55 ± 0.38 logarithm of the minimum angle of resolution units) improved to 0.46 ± 0.41 at 12 months after the initial PDT, at 24 months, it declined significantly to 0.59 ± 0.44 (P = .0018). Although only seven of 41 eyes exhibited VA deterioration at the 12-month follow-up examination, a decreased VA was noted in 18 eyes during the period starting from the 12-month follow-up until the final examination. The cases were bilateral in 11 (61.1%) of the 18 eyes. At the final examination, the mean VA of the bilateral cases but not the unilateral cases was significantly lower than that observed for the initial VA. Conclusions PDT is an effective treatment against PCV over the short-term for both unilateral and bilateral cases. However, the VA prognosis may not the same after 12 months, especially for those PCV patients who have exudative age-related macular degeneration in contralateral eye. To report on the two-year visual outcomes of indocyanine green angiography-guided photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients. Retrospective case study. A retrospective analysis that examined the clinical and angiographic data related to 41 eyes of 38 PCV patients (25 males, 13 females; average age ± standard deviation [SD], 72.9 ± 7.4 years) with follow-up periods of 24 months or more. The average number of PDT treatments was 1.65. After the 12-month follow-up, 12 eyes required retreatment. Although the mean visual acuity (VA) ± SD before PDT (0.55 ± 0.38 logarithm of the minimum angle of resolution units) improved to 0.46 ± 0.41 at 12 months after the initial PDT, at 24 months, it declined significantly to 0.59 ± 0.44 (P = .0018). Although only seven of 41 eyes exhibited VA deterioration at the 12-month follow-up examination, a decreased VA was noted in 18 eyes during the period starting from the 12-month follow-up until the final examination. The cases were bilateral in 11 (61.1%) of the 18 eyes. At the final examination, the mean VA of the bilateral cases but not the unilateral cases was significantly lower than that observed for the initial VA. PDT is an effective treatment against PCV over the short-term for both unilateral and bilateral cases. However, the VA prognosis may not the same after 12 months, especially for those PCV patients who have exudative age-related macular degeneration in contralateral eye." @default.
• W2167622011 created "2016-06-24" @default.
• W2167622011 creator A5049463882 @default.
• W2167622011 creator A5055321562 @default.
• W2167622011 creator A5070152065 @default.
• W2167622011 creator A5071086515 @default.
• W2167622011 creator A5071690549 @default.
• W2167622011 creator A5086219366 @default.
• W2167622011 creator A5087692428 @default.
• W2167622011 date "2008-10-01" @default.
• W2167622011 modified "2023-10-16" @default.
• W2167622011 title "Two-Year Results of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy" @default.
• W2167622011 cites W1481983591 @default.
• W2167622011 cites W1768895213 @default.
• W2167622011 cites W193593035 @default.
• W2167622011 cites W1966367482 @default.
• W2167622011 cites W1970803198 @default.
• W2167622011 cites W1974272630 @default.
• W2167622011 cites W1983733250 @default.
• W2167622011 cites W1987511165 @default.
• W2167622011 cites W1987722557 @default.
• W2167622011 cites W1993251139 @default.
• W2167622011 cites W2017033020 @default.
• W2167622011 cites W2036516882 @default.
• W2167622011 cites W2048050076 @default.
• W2167622011 cites W2048879382 @default.
• W2167622011 cites W2054180058 @default.
• W2167622011 cites W2064565985 @default.
• W2167622011 cites W2080591818 @default.
• W2167622011 cites W2097487722 @default.
• W2167622011 cites W2106178997 @default.
• W2167622011 cites W2755532609 @default.
• W2167622011 cites W4248773269 @default.
• W2167622011 cites W4249438516 @default.
• W2167622011 doi "https://doi.org/10.1016/j.ajo.2008.05.025" @default.
• W2167622011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18614133" @default.
• W2167622011 hasPublicationYear "2008" @default.
• W2167622011 type Work @default.
• W2167622011 sameAs 2167622011 @default.
• W2167622011 citedByCount "94" @default.
• W2167622011 countsByYear W21676220112012 @default.
• W2167622011 countsByYear W21676220112013 @default.
• W2167622011 countsByYear W21676220112014 @default.
• W2167622011 countsByYear W21676220112015 @default.
• W2167622011 countsByYear W21676220112016 @default.
• W2167622011 countsByYear W21676220112017 @default.
• W2167622011 countsByYear W21676220112018 @default.
• W2167622011 countsByYear W21676220112019 @default.
• W2167622011 countsByYear W21676220112020 @default.
• W2167622011 countsByYear W21676220112022 @default.
• W2167622011 crossrefType "journal-article" @default.
• W2167622011 hasAuthorship W2167622011A5049463882 @default.
• W2167622011 hasAuthorship W2167622011A5055321562 @default.
• W2167622011 hasAuthorship W2167622011A5070152065 @default.
• W2167622011 hasAuthorship W2167622011A5071086515 @default.
• W2167622011 hasAuthorship W2167622011A5071690549 @default.
• W2167622011 hasAuthorship W2167622011A5086219366 @default.
• W2167622011 hasAuthorship W2167622011A5087692428 @default.
• W2167622011 hasConcept C118487528 @default.
• W2167622011 hasConcept C141071460 @default.
• W2167622011 hasConcept C167135981 @default.
• W2167622011 hasConcept C178790620 @default.
• W2167622011 hasConcept C185592680 @default.
• W2167622011 hasConcept C2776403814 @default.
• W2167622011 hasConcept C2778257484 @default.
• W2167622011 hasConcept C2780248432 @default.
• W2167622011 hasConcept C2781065829 @default.
• W2167622011 hasConcept C2781323092 @default.
• W2167622011 hasConcept C2910234007 @default.
• W2167622011 hasConcept C71924100 @default.
• W2167622011 hasConceptScore W2167622011C118487528 @default.
• W2167622011 hasConceptScore W2167622011C141071460 @default.
• W2167622011 hasConceptScore W2167622011C167135981 @default.
• W2167622011 hasConceptScore W2167622011C178790620 @default.
• W2167622011 hasConceptScore W2167622011C185592680 @default.
• W2167622011 hasConceptScore W2167622011C2776403814 @default.
• W2167622011 hasConceptScore W2167622011C2778257484 @default.
• W2167622011 hasConceptScore W2167622011C2780248432 @default.
• W2167622011 hasConceptScore W2167622011C2781065829 @default.
• W2167622011 hasConceptScore W2167622011C2781323092 @default.
• W2167622011 hasConceptScore W2167622011C2910234007 @default.
• W2167622011 hasConceptScore W2167622011C71924100 @default.
• W2167622011 hasIssue "4" @default.
• W2167622011 hasLocation W21676220111 @default.
• W2167622011 hasLocation W21676220112 @default.
• W2167622011 hasOpenAccess W2167622011 @default.
• W2167622011 hasPrimaryLocation W21676220111 @default.
• W2167622011 hasRelatedWork W158348963 @default.
• W2167622011 hasRelatedWork W1963732392 @default.
• W2167622011 hasRelatedWork W1976600238 @default.
• W2167622011 hasRelatedWork W2051145347 @default.
• W2167622011 hasRelatedWork W2327683351 @default.
• W2167622011 hasRelatedWork W2402990751 @default.
• W2167622011 hasRelatedWork W2775800277 @default.
• W2167622011 hasRelatedWork W2982231913 @default.
• W2167622011 hasRelatedWork W3094668051 @default.
• W2167622011 hasRelatedWork W2083819917 @default.
• W2167622011 hasVolume "146" @default.

• next